Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer-Reference-Cited by-同舟云学术

Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer

Published:2012-09 Issue:13 Volume:48 Page:1932-1938
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bartsch Rupert,Bago-Horvath Zsuzsanna,Berghoff Anna,DeVries Catharina,Pluschnig Ursula,Dubsky Peter,Rudas Margaretha,Mader Robert M.,Rottenfusser Andrea,Fitzal Florian,Gnant Michael,Zielinski Christoph C.,Steger Guenther G.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference23 articles.

1. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced beast carcinoma;Bonneterre;Cancer,2001

2. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma;Bajetta;Cancer,2002

3. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer;Paridaens;Ann Oncol,2003

4. Molecular mechanisms of selective estrogen receptor modulator (SERM) action;Dutertre;J Pharmacol Exp Ther,2000

5. Aromatase inhibitors in breast cancer;Smith;N Engl J Med,2003

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung;Senologie - Zeitschrift für Mammadiagnostik und -therapie;2024-03

2. Preferences for the sequencing of first-line systemic treatments in metastatic hormone receptor-positive, HER2-negative breast cancer;Frontiers in Oncology;2023-10-18

3. Therapeutic potential of RUNX1 and RUNX2 in bone metastasis of breast cancer;Expert Opinion on Therapeutic Targets;2023-06-03

4. Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare;Geburtshilfe und Frauenheilkunde;2023-05-23

5. Personalisierte Medizin – innovative Therapiemöglichkeiten für das metastasierte Mammakarzinom;Der Gynäkologe;2022-04-22